NCT00159770已完成3 期
Tolerability, Safety, And Efficacy Of Ziprasidone (80 - 160 Mg/D) Versus Olanzapine (10 - 20 Mg/D), Risperidone (4 - 8 Mg/D) Or Quetiapine (300 - 750 Mg/D) In Pretreated Patients With Schizophrenia, Schizoaffective Disorder Or Schizophreniform Disorders - A 12-Week Open-Label, Multicenter Clinical Trial.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.44 个研究点 分布在 4 个国家目标入组 290 人开始时间: 2001年11月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 290
- 试验地点
- 44
- 主要终点
- PANSS (The Positive And Negative Syndrome Scale) in a 12 week period
研究概览
简要总结
Evaluation of the antipsychotic efficacy and safety of ziprasidone versus olanzapine, risperidone or quetiapine in patients with schizophrenia, schizoaffective and schizophreniform disorders under naturalistic conditions of clinical practice
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Inpatients or outpatients with schizophrenia, schizoaffective and schizophreniform disorders (DSM-IV).
- •Patients without adequate current treatment (i.e. intolerance to their current treatment or lack of efficacy of current treatment) based on clinical judgement of the investigator
排除标准
- •A history of intolerance to ziprasidone, olanzapine, risperidone or quetiapine or any of its ingredients
结局指标
主要结局
PANSS (The Positive And Negative Syndrome Scale) in a 12 week period
次要结局
- CGI-C score (Clinical Global Impression of Change), UKU-SERS-Pa (Patient self rating version). Safety and tolerability: ECG, serum cholesterol, triglycerides, prolactin, glucose and body weight
研究者
研究点 (44)
Loading locations...
相似试验
已完成
4 期
Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)SchizophreniaNCT00053703University of North Carolina, Chapel Hill116
Unknown
不适用
Efficacy and Safety of Ziprasidone to Treat Depressive Symptoms in Patients With SchizophreniaThe Primary Evaluation is the Change From Baseline at End of Study for CDSS Total Scores.The Secondary Efficacy Evaluations Include: MADRS, PANSS Total Scores and Subscales and Responder Rate; CGI-S and CGI-I Scales.Safety Evaluations Include: Laboratory Test Abnormalities; BARS and SAS; Physical Examinations; Vital Signs; Electrocardiogram,Etc.Subjective Well-being Under Neuroleptics Short Form Will be Used in Our Study to Assess the Subjective Side-effects.NCT01260116Wuhan University120
已完成
2 期
Ziprasidone for Severe Conduct and Other Disruptive Behavior DisordersConduct DisorderOppositional Defiant DisorderNCT00676429University Hospital Freiburg51
已完成
不适用
Treatment of Schizophrenic Patients With ZiprasidoneSchizophreniaNCT00579670Pfizer's Upjohn has merged with Mylan to form Viatris Inc.450
已完成
3 期
A Study Comparing the Efficacy and Tolerability of Ziprasidone vs. Clozapine for the Treatment of Schizophrenia in Patients Who Continue to Have Symptoms on or Cannot Tolerate Other Antipsychotic DrugsSchizophreniaNCT00649844Pfizer's Upjohn has merged with Mylan to form Viatris Inc.147